Interstitial Lung Disease Associated with Certolizumab Pegol Monotherapy in Psoriatic Arthritis

Author Information

Tan T. Tran, Drexel University College of MedicineFollow
Raesham Bukhari, Reading Hospital-Tower HealthFollow
Mahmood Danishwar, Reading Hospital-Tower HealthFollow
Mohammad Abu Tineh, Reading Hospital-Tower HealthFollow
Syed Jaleel, Reading Hospital-Tower HealthFollow

Keywords:

Certolizumab, Psoriatic arthritis, Interstitial lung disease, Drug-induced pneumonitis, TNF alpha inhibitor

Comments

mp4 file submission

Recommended Citation

Tran, Tan T.; Bukhari, Raesham; Danishwar, Mahmood; Abu Tineh, Mohammad; and Jaleel, Syed, "Interstitial Lung Disease Associated with Certolizumab Pegol Monotherapy in Psoriatic Arthritis" (2024). Tower Health Research Day. 32.
https://scholarcommons.towerhealth.org/th_researchday/2023-2024/in_person_posters/32

Institutional Review Board/Institutional Animal Care and Use Committee Approved or Exempt

Not Applicable